Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06671496 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06671496 · ClinicalTrials.gov record · last posted 2026-08-11

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

StatusRecruiting
PhasePhase 3
SponsorTakeda
Started2025-03-10
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.

Amendment record 17 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 17 times since 2024-10-31; most recent amendment 2026-06-26. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-03-12
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06671496
Lead Sponsor Takeda
Conditions Psoriatic Arthritis
Enrollment 600 participants
Start Date 2025-03-10
Primary Completion 2027-05-18 (estimated)
Study Completion 2028-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-11